ArticleDiagnostics (Basel, Switzerland)2021
Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting.
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis.Clinical and molecular hepatology · 2024Pooled it
- Effect of empagliflozin on liver fibrosis and steatosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized clinical trial.BMC endocrine disorders · 2025Trial
- Association of Subclinical Liver Fibrosis With Death in Patients With Coronary Artery Disease: A Post Hoc Analysis of the ISCHEMIA Trial.Journal of the American Heart Association · 2025Trial
- Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study.International journal of molecular sciences · 2025Trial
- Strong Family-Level Clustering of Adolescent Weight Status Despite Limited Associations with Individual Parental Anthropometric and Metabolic Characteristics.Journal of clinical medicine · 2026Article
- Functional liver imaging score in chronic liver disease: association with hepatocellular function and disease severity markers.Abdominal radiology (New York) · 2026Article
- Occupational heavy metal exposure and endocrine-metabolic biomarkers: a retrospective analysis of 34,595 screened individuals in Türkiye.BMC endocrine disorders · 2026Article
- Microbiome/transforming growth factor-β axis as a diagnostic and therapeutic target for MASLD in Egyptian patients.Gut pathogens · 2026Article
- Non-invasive liver fibrosis screening and referral patterns in women with dependence due to psychoactive substance use: A single-centre retrospective study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- From Policy to Practice: Knowledge gaps and training outcomes related to MASLD guidelines among medical officers in Chhattisgarh, India.BMC health services research · 2026Article
- Imaging-based fibrosis assessment and risk stratification in MASLD.Frontiers in medicine · 2026Review
- Development of a machine learning model to identify individuals with VCTE-derived at-risk MASH in a Spanish Mediterranean region.Frontiers in digital health · 2026Article
- Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease on Pattern and Management of Acute Coronary Syndrome.Saudi medical journal · 2026Article
- Evaluation of Prognosis in Cirrhotic Patients with Esophageal Variceal Bleeding Using Non-Invasive Scores.Medicina (Kaunas, Lithuania) · 2025Article
- Liver Fibrosis as a Predictor of Cardiovascular Risk in Patients with Severe Obesity.Journal of clinical medicine · 2025Article
- Implementation of noninvasive liver disease screening tools in primary care.Korean journal of family medicine · 2025Article
- Redefining the albumin-bilirubin score: Predictive modeling and multidimensional integration in liver and systemic disease.World journal of gastroenterology · 2025Article
- Simple scoring model for predicting overt hepatic encephalopathy in geriatric cirrhosis: A multicenter retrospective cohort study.Metabolic brain disease · 2025Article
- Correlations BetweenLife (Basel, Switzerland) · 2025Article
- FIB-4 Score as a Predictor of Eligibility for Elastography Exam in Patients with Polycystic Ovary Syndrome.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver disease is frequently asymptomatic, challenging early identification in the primary care setting. The fibrosis 4 (FIB4) index is a liver fibrosis biomarker that is a potential alternative to liver biopsy for diagnosing and managing liver disease. This study aimed to calculate the FIB4 index for screening individuals at high risk of liver disease at the community level. This was a retrospective real-world study analyzing blood and serum test results from a central laboratory. The primary outcome was the number of individuals within each risk category for hepatic fibrosis: high risk (FIB4 ≥ 3.25) and low risk (FIB4 < 1.3). The analysis included samples from 31,753 patients, of which 18,102 were aged 40 to 75 years. In these patients, the FIB4 index had been explicitly requested in 1852 (10.2%) cases and estimated ad hoc in the rest. Of the 263 (1.5%) cases with FIB4 ≥ 3.25, the FIB4 index was requested in 46 (17.5%), and 52 (19.8%) showed evidence of liver fibrosis in their medical records, while the rest did not report any data regarding liver fibrosis. FIB4 is a simple score that can play a role as a "red flag" for early identification of patients at high risk of advanced liver fibrosis and their referral to specialized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.